ReviewTrends in immunology2013
Basic principles of tumor-associated regulatory T cell biology.
Review in Trends in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 102 citations in OpenAlex.
- Human cytomegalovirus latency-associated proteins elicit immune-suppressive IL-10 producing CD4⁺ T cells.PLoS pathogens · 2013Trial
- Ovarian cancer tumor immune profiles associated with intrauterine device and oral contraceptive use.British journal of cancer · 2026Article
- KLF5-driven TAZ-FASN signaling reprograms fatty acid metabolism to support Treg differentiation in lung cancer.Journal of translational medicine · 2026Article
- Puerarin Targets MIC19 to Suppress Mitochondrial Metabolism of Tumor-Infiltrating Tregs and Enhance Anti-tumor Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Colorectal Cancers and Immunotherapy.Cancer treatment and research · 2025Review
- Foxp3 inhibitory peptide encapsulated in a novel CD25-targeted nanoliposome promotes efficient tumor regression in mice.Acta pharmacologica Sinica · 2025Article
- Control of T-cell immunity by fatty acid metabolism.Annals of pediatric endocrinology & metabolism · 2024Article
- Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review.Journal of translational medicine · 2024Review
- Ultrasound-targeted microbubble destruction remodels tumour microenvironment to improve immunotherapeutic effect.British journal of cancer · 2023Review
- Chimeric antigen-receptor (CAR) engineered natural killer cells in a chronic myeloid leukemia (CML) blast crisis model.Frontiers in immunology · 2023Article
- Mitochondrial CPT1A: Insights into structure, function, and basis for drug development.Frontiers in pharmacology · 2023Review
- Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition.Molecular cancer · 2022Review
- DeCAF: a novel method to identify cell-type specific regulatory variants and their role in cancer risk.Genome biology · 2022Article
- The effects of TNF-α/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer.International journal of cancer · 2022Article
- CD8Nature reviews. Immunology · 2022Review
- Tumor budding as a predictor for prognosis and therapeutic response in gastric cancer: A mini review.Frontiers in oncology · 2022Review
- Reinventing the human tuberculosis (TB) granuloma: Learning from the cancer field.Frontiers in immunology · 2022Review
- Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study.Frontiers in immunology · 2022Observational
- Intratumoral density of regulatory T cells is a predictor of host immune response and chemotherapy response in colorectal cancer.American journal of cancer research · 2022Article
- The Prognostic Value of FoxP3+ Tumour-Infiltrating Lymphocytes in Rectal Cancer Depends on Immune Phenotypes Defined by CD8+ Cytotoxic T Cell Density.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Due to the critical role of forkhead box (Fox)p3(+) regulatory T cells (Tregs) in the regulation of immunity and the enrichment of Tregs within many human tumors, several emerging therapeutic strategies for cancer involve the depletion or modulation of Tregs, with the aim of eliciting enhanced antitumor immune responses. Here, we review recent advances in understanding of the fundamental biology of Tregs, and discuss the implications of these findings for current models of tumor-associated Treg biology. In particular, we discuss the context-dependent functional diversity of Tregs, the developmental origins of these cells, and the nature of the antigens that they recognize within the tumor environment. In addition, we highlight critical areas of focus for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.